Vinca Alkaloid Dipeptide Prodrugs for Targeted Tumor Activation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current vinca alkaloid drugs used in cancer treatment and other conditions like diabetic retinopathy and rheumatoid arthritis have significant toxic side effects and limited therapeutic efficacy due to their non-specific action on both normal and tumor cells.
Innovation Solution
Development of vinca alkaloid dipeptide derivatives and hydrazinolyzed vinca alkaloids that are specifically activated by fibroblast-activation protein alpha (FAPα), reducing toxicity and enhancing therapeutic effects by targeting tumor cells while sparing normal cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If vinca alkaloid drugs are used to treat cancer and other conditions, then therapeutic effects are achieved, but toxic side effects occur due to non-specific action on normal and tumor cells
Solution Approach 1:
The patent segments the drug delivery process into two distinct phases: (1) administration of inactive prodrug forms that do not bind to tubulin, and (2) selective activation at the target site. This segmentation allows the drug to avoid systemic toxicity while maintaining therapeutic efficacy through localized conversion to the active form by FAPα enzyme present in tumor tissues.
Solution Approach 2:
The patent introduces FAPα enzyme as an intermediary that mediates the conversion of inactive vinca alkaloid derivatives to their active forms. This intermediary mechanism enables selective drug activation specifically at tumor sites where FAPα is overexpressed, preventing systemic toxicity while ensuring therapeutic action where needed.
2Reliability
If vinca alkaloid drugs are administered systemically, then tumor cells are targeted, but normal cells are also affected causing toxicity
Solution Approach 1:
The patent applies local quality by designing vinca alkaloid derivatives with modified chemical structures that prevent binding to tubulin in normal tissues, while these same derivatives can be selectively activated by FAPα enzyme only in tumor tissues. This creates different functional properties in different locations: inactive and non-toxic in normal tissues, active and therapeutic in tumor tissues.
Solution Approach 2:
The patent changes the chemical parameters of vinca alkaloids by modifying their molecular structure to create prodrugs that cannot bind to tubulin in their inactive form. These parameter changes include modifications to the indole rings and side chains, which are then reversed through enzymatic activation at the target site to restore antitumor activity selectively.
3Adaptability or versatility
If conventional vinca alkaloids are used, then broad-spectrum anticancer activity is achieved, but therapeutic window is limited due to side effects
Solution Approach 1:
The patent introduces dynamics into the drug system by creating convertible prodrugs that can dynamically switch between inactive and active states. The vinca alkaloid derivatives remain inactive during circulation and administration, then dynamically activate upon encountering FAPα enzyme at the tumor site, allowing broad-spectrum activity across different tumor types while maintaining a wide therapeutic window.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The vinca alkaloid derivatives demonstrate reduced toxicity and improved efficacy in inhibiting tumor growth, angiogenesis, and disrupting new blood vessel formation, with significant effects on malignant tumors, diabetic retinopathy, and rheumatoid arthritis, as shown by in vitro and in vivo studies.
Implementation Method 1
specifically activated by fibroblast-activation protein alpha (FAPα)
Implementation Method 2
hydrazinolyzed vinca alkaloids
Data Source
AI summary
The present invention provides a new kind of vinca alkaloid derivatives, new applications thereof and preparation methods therefor. The vinca alkaloid derivatives comprise hydrazinolyzed vinca alkaloids and vinca alkaloid dipeptide derivative. The hydrazinolyzed vinca alkaloids are the compounds obtained from the reaction of vinca alkaloids or salts thereof with hydrazinolyzed hydrate; and the vinca alkaloid dipeptide derivatives are the compounds obtained from the condensation of hydrazinolyzed vinca alkaloids with N-benzyloxycarbonylglycyl proline. The present invention provides the uses of the vinca alkaloids derivatives or the pharmaceutical compositions thereof in anti-tumor, preventing or treating diabetic retinopathy, rheumatoid arthritis and serving as angiogenesis inhibitors or vascular disrupting agents.